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Abstract 
We present here a case of dorsal column degeneration in a female patient with multiple 
myeloma following exposure to bortezomib. Two days after intravenous administration 
of a first course of bortezomib 1 mg/m2, the patient developed rapidly-progressive 
numbness, pain and muscle weakness in the bilateral upper and lower limbs. Following 
gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to 
receive a course of EPOCH (etoposide 50 mg/m2/day on days 1–4, vincristine 
0.4 mg/m2/day on days 1–4, doxorubicin 10 mg/m2/day on days 1–4, cyclophosphamide 
750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1–6). Shortly 
thereafter, the patient developed bilateral Aspergillus pneumonia. Despite treatment 
with appropriate antifungal agents, the patient died from respiratory failure due to 
bilateral diffuse alveolar damage of the lungs and without recovery of severe sensory 
and motor neuropathy prior to her death. Post mortem examination revealed spongy 
degeneration of the dorsal column from the medulla oblongata to the cervical spinal 
cord. Bortezomib-associated peripheral neuropathy in patients with multiple myeloma 
has been commonly reported but appears to resolve in a majority of these patients after 
dose reduction or discontinuation. We believe this to be the first report of spinal cord 
abnormalities in a patient with multiple myeloma treated with bortezomib. Further 
investigation is required to ascertain the exact mechanism of this central neurotoxic 
effect and to identify appropriate neuroprotective strategies. 
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Introduction 
Multiple myeloma remains an incurable hematological disorder. Bortezomib, the first-
in-class proteasome inhibitor, has been shown to have significant antitumor activity in 
the treatment of relapsed/refractory patients with this condition [1, 2]. The main dose-
limiting toxicity of bortezomib is peripheral neuropathy, which requires dose 
modification and potential changes to the treatment plan when present [3]. The precise 
mechanism of this toxicity is not fully understood. Herein we report a case of 
degeneration of the dorsal column of the central nervous system from the medulla 
oblongata to the cervical spinal cord in a patient with multiple myeloma after a first 
course of bortezomib chemotherapy. Despite no further exposure to bortezomib, the 
patient’s neurological abnormalities failed to show any resolution prior to her death. 
Eventual cause of death was respiratory failure due to bilateral diffuse alveolar damage of 
the lungs. 
Case Presentation 
A 64-year-old female patient was diagnosed with multiple myeloma (IgG, κ light-chain isotype, stage 
IIIA) in May 2008. Laboratory examination revealed elevation of serum IgG (2,196 mg/dl), IgG-κ type 
Bence-Jones protein in urine, proliferation of multiple myeloma cells in sternum bone marrow (about 
54%), anemia (hemoglobin 7.9 g/dl), hypercalcemia (11.5 mg/dl), elevation of serum β2 microglobulin 
(8.8 mg/l), and multiple osteolytic lesions, including pathological fractures (cranium, clavicular bones, 
scapulas, radial bones, brachia, femurs, and tibiae). As initial treatment, dexamethasone 40 mg/day on 
days 1–4 along with zoledronic acid hydrate 4 mg on day 1 was administered intravenously from 28 
May 2008. On 4 June 2008, a herpes zoster skin eruption appeared on the lower left limb, which was 
treated with acyclovir. Following healing of the skin eruption, bortezomib 1 mg/m
2 was administered 
intravenously on days 1, 4, 8 and 11 from 24 June to 4 July 2008. On 6 July 2008, the patient developed 
numbness, pain and muscle weakness in the bilateral upper and lower limbs. The symptoms progressed 
rapidly and the patient was bedridden within a few days. Magnetic resonance imaging of the brain and 
whole spine failed to reveal any abnormalities including cord compression. Treatment with vitamin B12 
was ineffective. Cytomegalovirus (CMV) infection was detected on 25 July 2008 and treated with 
gancyclovir. After improvement of CMV viremia, a course of EPOCH chemotherapy (etoposide 50 
mg/m
2/day on days 1–4, vincristine 0.4 mg/m
2/day on days 1–4, doxorubicin 10 mg/m
2/day on days  
1–4, cyclophosphamide 750 mg/m
2/day on day 6, and prednisolone 60 mg/m
2/day on days 1–6) was 
administered beginning on 21 August 2008. Bilateral Aspergillus pneumonia occurred on 5 September 
2008. Despite treatment with appropriate antifungal agents, the patient died in the autumn of 2008 from 
respiratory failure without recovery of severe sensory and motor neuropathy. 
Post mortem examination revealed spongy degeneration of the dorsal column from the medulla 
oblongata to the cervical spinal cord, which likely triggered the neurological abnormalities. Spongy 
degeneration of the dorsal column was noted by hematoxylin-eosin staining, and damage to neuron and 
neural fibers was ascertained by luxol fast blue staining (fig. 1). As regards the patient’s multiple 
myeloma, only remnants of myeloma cells were observed in the bone marrow, and there was no 
evidence of myeloma cell infiltration to other organs, indicating that chemotherapy including 
bortezomib was effective. Bilateral diffuse alveolar damage of the lungs was determined as the cause of 
death; however, no trace of fungal or bacterial pneumonia was evident. 
Discussion 
Bortezomib-induced peripheral neuropathy has been commonly reported [3, 4] but, to 
our knowledge, there have been no reports to date of spinal cord abnormalities in patients 
with multiple myeloma treated with bortezomib. After administration of bortezomib in a 
Wistar rat model, mild-to-moderate pathological changes in Schwann cells and myelin 
were observed along with satellite cell intracytoplasmic vacuolization in the dorsal root 
ganglia due to mitochondrial and endoplasmic reticulum damage; however, the spinal  
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cord was confirmed as morphologically normal in this model [5]. In the present case, the 
patient had not previously been exposed to other neurotoxic agents such as vincristine or 
thalidomide, and severe progressive neurological abnormalities appeared after the first 
course of bortezomib. Although the peripheral neuropathy associated with bortezomib 
appears to be reversible in a majority of patients after dose reduction or discontinuation 
[4], no resolution of central neurological abnormalities was observed in this patient prior 
to her death. 
In summary, we have experienced a multiple myeloma patient with spongy 
degeneration of the dorsal column from the medulla oblongata to the cervical spinal cord 
after bortezomib treatment. The neurological abnormalities were severe and irreversible. 
Bortezomib is a promising salvage agent for relapsed/refractory multiple myeloma; 
however, the associated nerve damage and its development are unpredictable at present. 
Further investigation is required to clarify the mechanism of bortezomib-induced 
neurotoxicity and to develop effective prevention and treatment methods against such an 
effect. 
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Fig. 1. Spongy degeneration of the spinal cord dorsal column in a patient with multiple myeloma.  
a, c Hematoxylin-eosin staining; loupe and ×40. b, d Luxol fast blue staining; ×40 and ×200. 
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